Skip to content
Company Analysis

Cytek Biosciences, Inc. CTKB

A comprehensive view of key metrics, scores, and financial health for Cytek Biosciences, Inc.

Overview of Cytek Biosciences, Inc.

CTKB NMS
Healthcare Medical Devices Small Cap
Cytek Biosciences, Inc. (CTKB), is a Small Cap company, in the Medical Devices industry, last closed at $4.01, about 33.2% overvalued vs fair value, -8.0% 1Y return, placing in the top 25% of its sector.
$4.01
0.25%
As of March 13, 2026
Previous close • Vol 90d: 61.2%
52-Week Range
Market Cap
$515.49M
Enterprise Value
$447.03M
Overall Score
Scores locked

Create a free account to see overall and pillar scores for Cytek Biosciences, Inc..

Top Beats

Quick Facts

Website https://cytekbio.com
HQ Fremont, CA
Employees 692
Fiscal year Dec 31

Next Events

Earnings May 7 Estimated

Fair Value Snapshot

Bear Base Bull
$2
$3
$3
Current: $4.01 -33% vs base

Engine Room Money Flow™

Small Cap

Corporate Free Cash Flow - Where revenue goes and how value is created

Flow Steps
Revenue
$200.5M
3.9%%
Gross Profit
$111.1M
1.5%%
Operating Income
$-20.5M
26.3%%
Net Income
$-6.0M
50.4%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Corporate Free Cash Flow

Quality & Reliability Indicators

Cash Conversion Ratio
-359.6%
Poor

FCF / Net Income - measures how well earnings convert to cash

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Owner's Pocket - Capital Allocation

Total Returned to Shareholders

Combined dividends, buybacks, and debt reduction

$23.1M
106.6% of FCF

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
3
Active Leaks
3/3
Improving
1
High Impact
2
Critical
Locked Leak
Upgrade to view details
Premium
Locked Leak
Upgrade to view details
Premium
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Cytek Biosciences, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
64
/100
Moderate
Scores based on quantitative metrics and qualitative factors

Upgrade to unlock interactive defense details

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Moderate
58
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger™

Where management spends the performance budget - Growth, Profitability, or Safety

Generic Industrial / Default vs Industry Peers 92% Coverage
Trade-Off Triangle Visualization A ternary plot showing CTKB's balance between Growth (31.7%), Profitability (38.1%), and Safety (30.3%). Growth 32% Safety 30% Profitability 38%

Click axes to expand details. Marker shows current allocation.

3-Year Trend Analysis Locked
Upgrade to unlock the full 3-year trend analysis and deltas.

Growth

55th percentile vs peers
56
Key Signals
Revenue CAGR 3Y 16.1% 62p EPS Growth YoY 50.4% 69p Rev Growth YoY 3.9% 40p
Strengths
  • Superior capital returns - 3 return metrics above peer median
  • Fcf Margin in top 20% of peers (10.8%, 82th percentile)
  • Cash Flow To Debt Ratio in top 20% of peers (1.37, 89th percentile)
  • Consistently strong margins across 6 metrics
Risks

No significant risks identified for this axis.

Profitability

66th percentile vs peers
67
Key Signals
Strengths
Risks
Premium
Unlock full Profitability drilldowns

See the signal-level drivers and insights behind this axis. Upgrade to reveal the full Trade-Off Ledger.

Upgrade Now

Safety

53th percentile vs peers
53
Key Signals
Strengths
Safety drilldowns are available to premium members.

Two Futures

Scenario-based fair value ranges for Cytek Biosciences, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$2.68
- - -
-33.2% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info